Document Detail

Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
MedLine Citation:
PMID:  22697264     Owner:  NLM     Status:  In-Data-Review    
Pirfenidone has been shown in three recently published trials to slow down the progression of the devastating interstitial lung disease, idiopathic pulmonary fibrosis (IPF). The precise mechanisms that initiate and perpetuate the histopathological process leading to lung fibrosis in IPF are still uncertain, but increased concentrations of reactive oxidative species and fibrogenetic factors have been observed in the pulmonary tissue of patients. Although the exact mechanisms of its action are unknown, pirfenidone is a small molecule with antifibrotic and some hydroxyl scavenger properties that has recently been approved in Europe and elsewhere for the treatment of IPF. Along with the new ATS/ERS/JRS/ALAT 2011 statement for 'Evidence Based Guidelines for Diagnosis and Management', there is now a more profound basis for offering IPF patients an evidence-based evaluation and treatment. This review summarizes the background to the recommended use of pirfenidone for the treatment of IPF. Please cite this paper as: Hilberg O, Simonsen U, du Bois R and Bendstrup E. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin Respir J 2012; 6: 131-143.
Ole Hilberg; Ulf Simonsen; Roland du Bois; Elisabeth Bendstrup
Related Documents :
22782844 - Flow diversion to treat aneurysms: the free segment of stent.
19823174 - Effects of sulfur dioxide on hypoxic pulmonary vascular structural remodeling.
10940364 - The effect of the nitric oxide synthase inhibitor n-gamma-nitro-l-argine methyl ester o...
22743144 - Techniques available for hemodynamic monitoring. advantages and limitations.
19669984 - Common origin of the artery of adamkiewicz and a posterior spinal artery with a spinal ...
24866604 - Exploring carotid sonographic parameters associated with stroke risk among hypertensive...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The clinical respiratory journal     Volume:  6     ISSN:  1752-699X     ISO Abbreviation:  Clin Respir J     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101315570     Medline TA:  Clin Respir J     Country:  England    
Other Details:
Languages:  eng     Pagination:  131-43     Citation Subset:  IM    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Aarhus University Hospital, Respiratory Diseases and Allergology, Aarhus, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Can object affordances impact on human social learning of tool use?
Next Document:  Yeast glucose pathways converge on the transcriptional regulation of trehalose biosynthesis.